Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1273.214
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
mRNA-1273.214 is a bivalent mRNA-based vaccine developed by Moderna for the prevention of COVID-19. It is composed of two messenger RNA (mRNA) sequences: one encoding the spike protein of the original SARS-CoV-2 strain (Wuhan-Hu-1) and another encoding the spike protein of the Omicron BA.1 variant. These mRNAs are encapsulated within lipid nanoparticles (LNPs) to facilitate delivery into host cells, where they are translated into viral proteins that trigger an immune response. mRNA-1273.214 was the first bivalent COVID-19 booster to receive regulatory authorization, providing enhanced protection against the Omicron variant compared to the original monovalent vaccine. While it has been utilized as a comparator in clinical trials for multi-component vaccines targeting influenza and respiratory syncytial virus (RSV), such as mRNA-1230, mRNA-1273.214 itself is exclusively a COVID-19 vaccine and does not contain antigens for other respiratory pathogens.
- Brand names
- Spikevax Bivalent Original/Omicron BA.1
- Other names
- Moderna COVID-19 Vaccine, Bivalent (Original and Omicron BA.1)
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on mRNA-1273.214.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1273.214.